Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in Novome Biotechnologies, a clinical-stage company that develops engineered oral microbial therapies.
| Innovative platform to enable oral delivery of biologics for the treatment of chronic diseases HARLEYSVILLE, Pa., Sept. 15, 2022 /PRNewswire/ -- Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in Novome Biotechnologies, a clinical-stage company that develops engineered oral microbial therapies. The company’s novel delivery platform controls the colonization of therapeutically engineered bacteria, enabling first-in-class treatment of chronic disorders such as inflammatory bowel disease and enteric hyperoxaluria.
Ali Rajabi-Siahboomi, Vice President and Chief Innovation Officer at Colorcon, said, “Novome is aligned with Colorcon Ventures’ interest in oral delivery of new therapeutic modalities. The company is pioneering a class of oral biologics with an impressive pace of scientific achievement. We look forward to supporting Novome as they realize the full potential of their platform.” Blake Wise, Novome’s CEO, said, “We are pleased to have the support of Colorcon Ventures as we expand the capabilities of our delivery platform. Colorcon’s global relationships and oral formulation expertise will add value to our next phase of growth.” Colorcon Ventures joins a prominent list of investors who also participated in Novome’s recently announced Series B, including Tencent, DCVC Bio, 5AM Ventures, Alta Partners and Alexandria Venture Investments. About Colorcon Ventures About Novome Genetically Engineered Microbial Medicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its proof-of-concept program in enteric hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to decrease the risk of kidney stone formation. Significant progress has also been made with earlier-stage programs enabling local delivery of high amounts of therapeutic protein cargo for the potential treatment of inflammatory bowel disease. Efforts are also directed toward advancing additional pipeline indications in irritable bowel syndrome and immuno-oncology. For more information, please visit the Novome Biotechnologies website at https://novomebio.com/ Logo - https://mma.prnewswire.com/media/996844/Colorcon_Ventures_Logo.jpg
SOURCE Colorcon Ventures |
View original content to download multimedia:
